Antianxiety effect of cannabidiol in the elevated plus-maze
- 1 April 1990
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 100 (4), 558-559
- https://doi.org/10.1007/bf02244012
Abstract
In order to assess the presence of anxiolytic properties in cannabidiol (CBD) the drug was tested in an elevated plus-maze model of anxiety, in rats. Doses of 2.5, 5.0 and 10.0 mg/kg significantly increased the entry ratio (open/total number of entries), an anxiolytic-like effect. CBD at a dose of 20.0 mg/kg was no longer effective. None of the doses of CBD used changed total number of entries, a measure of total exploratory activity. Diazepam (2.0 mg/kg) also caused an anxiolytic-like effect in this model. These results indicate that CBD causes a selective anxiolytic effect in the elevated plusmaze, within a limited range of doses.This publication has 7 references indexed in Scilit:
- Antianxiety effect of cannabidiol in the elevated plus-mazePsychopharmacology, 1990
- Cannabinoid pharmacology.1986
- Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the ratPharmacology Biochemistry and Behavior, 1986
- Validation of open : closed arm entries in an elevated plus-maze as a measure of anxiety in the ratJournal of Neuroscience Methods, 1985
- Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjectsPsychopharmacology, 1982
- Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic PatientsPharmacology, 1980
- Comparison of four vehicles for intraperitoneal administration of Δ1-tetrahydrocannabinolJournal of Pharmacy and Pharmacology, 1971